Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TGT-101
Therapeutic Area : Ophthalmology
Study Phase : Discovery
Sponsor : mCureX
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The two companies plan to conduct gene corrections in ocular tissues using mCureX's mRNA technology and ToolGen's TGT-101 & CRISPR/Cas9 gene-editing technology for the treatment of rare hereditary eye diseases.
Brand Name : TGT-101
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 15, 2022
Lead Product(s) : TGT-101
Therapeutic Area : Ophthalmology
Highest Development Status : Discovery
Sponsor : mCureX
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?